Randomized Controlled Trial

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

N. Engl. J. Med. 2017 Sep 21; 377 (12): 1119-1131.
Article

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.

Lancet. 2018 Jan 27; 391 (10118): 319-328.
Randomized Controlled Trial

Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the...

Eur. Heart J. 2020 Jun 14; 41 (23): 2153-2163.